An analysis of shareholders’ reactions to clinical data shows a generally dismal environment punctuated by a few huge positive moves.

Slam-dunk mid-stage data in liver cancer send TPST-1120 towards a pivotal trial, though Tempest will need both cash and a partner to fulfil the PPAR⍺ antagonist’s potential.

The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.

Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.